Search Close


Director Share Dealing

21st October 2013

The Company has been notified that on 21 October 2013 Lindy Durrant and Richard Goodfellow each sold 100,000 shares in the Company from their respective holdings held jointly with Scancell Employee Benefit Trust at a price of 30 pence per share.

Following these transactions their holdings in the Company are as follows:


Director Name

No. of shares held in own sole name post transaction


No. of shares held jointly with Scancell Employee Benefit Trust post transaction


Lindy Durrant




Richard Goodfellow





For Further Information:


Scancell Holdings Plc 

+ 44 (0) 20 7831 3113 

Dr Richard Goodfellow, Joint CEO 


Professor Lindy Durrant, Joint CEO 




Cenkos Securities plc:

+44 (0) 20 7397 8900

Camilla Hume


Stephen Keys




FTI Consulting

+44 (0) 20 7831 3113

Simon Conway


Mo Noonan




Dr. Reuter Investor Relations

+(0) 49 251 980 1561

Kim von Ahn


Webcasts, Interviews and Media Coverage

Scancell welcomes strategic new investor Vulpes Life Sciences Fund

Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.

The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.

Thu, 13 Jun 2019 09:53:00

Scancell raises £3.9mln to advance immunotherapy product pipeline

“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”

Thu, 13 Jun 2019 06:31:00

Scancell exploring new frontiers in cancer research

Here we take a closer look at Scancell, which is at the vanguard of immuno-oncology

Mon, 20 May 2019 09:51:00